Multi-Organ System Screening, Care, and Patient Support in Systemic Sclerosis.

Systemic sclerosis (SSc) is a heterogenous systemic autoimmune disease of complex multi-organ manifestations with a disease-specific mortality of >50%. The patient journey is fraught with severe, diverse, and diffuse physical impairment, psychological burden, and diminishing health-related quality of life. SSc remains unfamiliar to many clinicians. Delayed/misdiagnosis, inadequate screening, and attention for common complications with potentially preventable disability/death contribute to patients feeling isolated and unsupported. We present actionable standards including screening, anticipatory guidance, and counseling in patient-centered SSc-care emphasizing psycho-social health as the central goal, whereas robust vigilance and efforts to improve biophysical health and survival are imperatives that support this goal.

• Publication year

  2023

• Venue

  Rheumatic Disease Clinics of North America

• Publication date

  2023-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rdc.2023.01.002PMID 37028832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patient Experience of Systemic Sclerosis-Related Calcinosis: An International Study Informing Clinical Trials, Practice, and the Development of the Mawdsley Calcinosis Questionnaire.

  2023cited by this paper
• Promoting early management of frailty in the new normal: An updated software tool in addressing the need of virtual assessment of frailty at points of care

  2022cited by this paper
• Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study

  2022cited by this paper
• Depression and loneliness may predict work inefficiency among professionally active adults

  2022cited by this paper
• Myokines and Resistance Training: A Narrative Review

  2022cited by this paper
• Ageing with Interstitial lung disease: preserving health and well being

  2022cited by this paper
• How do patients define Raynaud’s phenomenon? Differences between primary and secondary disease

  2021cited by this paper
• Prevalence of Sexual Dysfunction in People With Systemic Sclerosis and the Associated Risk Factors: A Systematic Review

  2021cited by this paper
• Validity and reliability of the Swedish version of the Self-Efficacy for Managing Chronic Disease scale for individuals with systemic sclerosis

  2021cited by this paper
• Erectile function and connective tissue diseases. Prevalence of erectile dysfunction in German men with systemic sclerosis compared to other connective tissue diseases and healthy subjects.

  2021cited by this paper
• Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

  2021cited by this paper
• Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis

  2021cited by this paper
• The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort.

  2021cited by this paper
• Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study

  2021cited by this paper
• Sensitivity to change of joint count composite indices in 72 patients with systemic sclerosis.

  2021cited by this paper
• Employment outcomes in systemic sclerosis.

  2021cited by this paper
• Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modeling approach.

  2021cited by this paper
• Screening rates and prevalence of osteoporosis in a real‐world, Australian systemic sclerosis cohort

  2021cited by this paper
• A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

  2021cited by this paper
• Diagnostic measures for patients with systemic sclerosis-associated myopathy.

  2021cited by this paper
• Patient experiences of digital ulcer development and evolution in systemic sclerosis.

  2020cited by this paper
• Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis

  2020cited by this paper
• Natural history of systemic sclerosis–related interstitial lung disease: How to identify a progressive fibrosing phenotype

  2020cited by this paper
• ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

  2020cited by this paper
• Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis

  2020cited by this paper
• Sexual function in German women with systemic sclerosis compared to women with systemic lupus erythematosus and evaluation of a screening test.

  2020cited by this paper
• Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach

  2020cited by this paper
• Assessment of loneliness in patients with inflammatory arthritis

  2020cited by this paper
• Sleep Disturbance in Scleroderma

  2020cited by this paper
• Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis

  2020cited by this paper
• Longitudinal analysis of loneliness and inflammation at older ages: English longitudinal study of ageing.

  2019cited by this paper
• The patient experience of Raynaud’s phenomenon in systemic sclerosis

  2019cited by this paper
• Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden

  2019cited by this paper
• Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis

  2019cited by this paper
• Musculoskeletal hand involvement in systemic sclerosis.

  2019cited by this paper
• Cardiac complications in systemic sclerosis: early diagnosis and treatment

  2019cited by this paper
• Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient‐Reported Assessments of Disease Severity

  2019cited by this paper
• Vaccination coverage in children with rheumatic diseases.

  2019cited by this paper
• Geographic disparity in systemic sclerosis mortality in the United States: 1999–2017

  2019cited by this paper
• Reasons for not participating in scleroderma patient support groups: a comparison of results from the North American and European scleroderma support group surveys

  2019cited by this paper
• Wrist-Sensor Pulse Oximeter Enables Prolonged Patient Monitoring in Chronic Lung Diseases

  2019cited by this paper
• Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases

  2019cited by this paper
• Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study

  2019cited by this paper
• Common Causes of Pain in Systemic Sclerosis: Frequency, Severity, and Relationship to Disease Status, Depression, and Quality of Life.

  2019cited by this paper
• Myocardial fibrosis detected by magnetic resonance imaging, elevated U-CRP and higher mRSS are predictors of cardiovascular complications in systemic sclerosis (SSc) patients.

  2019cited by this paper
• Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis

  2019cited by this paper
• Measuring and managing appearance anxiety in patients with systemic sclerosis

  2019cited by this paper
• Multifactorial explanatory model of depression in patients with rheumatoid arthritis: a structural equation approach.

  2019cited by this paper
• Exploring the patient experience of digital ulcers in systemic sclerosis.

  2019cited by this paper
• Patient-reported outcome instruments in clinical trials of systemic sclerosis

  2019cited by this paper
• Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study

  2019cited by this paper
• Wildflowers abundant in the garden of systemic sclerosis research, while hopeful exotics will one day bloom.

  2018cited by this paper
• The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis

  2018cited by this paper
• Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin

  2018cited by this paper
• Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating ‘not applicable’ responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study

  2018cited by this paper
• Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

  2018cited by this paper
• Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen

  2018cited by this paper
• Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis

  2018cited by this paper
• Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group

  2018cited by this paper
• Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study

  2018cited by this paper
• Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

  2018cited by this paper
• Improved Cough and Cough‐Specific Quality of Life in Patients Treated for Scleroderma‐Related Interstitial Lung Disease: Results of Scleroderma Lung Study II

  2017cited by this paper
• Points to consider for designing trials in systemic sclerosis patients with arthritic involvement

  2017cited by this paper
• Mapping and predicting mortality from systemic sclerosis

  2017cited by this paper
• Brief Report: Anti–RNPC‐3 Antibodies As a Marker of Cancer‐Associated Scleroderma

  2017cited by this paper
• Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.

  2017cited by this paper
• Musculoskeletal Involvement in Systemic Sclerosis: An Unexplored Aspect of the Disease

  2017cited by this paper
• Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and/or immunosuppressive therapies for systemic autoimmune diseases: A cross-sectional study.

  2017cited by this paper
• Systemic sclerosis: Sexual dysfunction and lower urinary tract symptoms in 73 patients.

  2016cited by this paper
• Current management of the gastrointestinal complications of systemic sclerosis

  2016cited by this paper
• Erectile Dysfunction in Systemic Sclerosis

  2016cited by this paper
• Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study.

  2016cited by this paper
• BSR and BHPR guideline for the treatment of systemic sclerosis.

  2016cited by this paper
• UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis.

  2016cited by this paper
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

  2016cited by this paper
• Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis

  2015cited by this paper
• Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography.

  2015cited by this paper
• Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

  2015cited by this paper
• Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD).

  2015cited by this paper
• The clinical relevance of sexual dysfunction in systemic sclerosis.

  2015cited by this paper
• Systemic Sclerosis: Gastrointestinal Disease and Its Management.

  2015cited by this paper
• SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN.

  2015cited by this paper
• Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer‐Associated Scleroderma

  2015cited by this paper
• Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.

  2015cited by this paper
• AB0712 Development of a “Renal Crisis Prevention Card” as an Education Tool to Improve Outcomes in High Risk Patients with Systemic Sclerosis (SSC)

  2015cited by this paper
• Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry

  2015cited by this paper
• Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

  2014cited by this paper
• Work participation in patients with systemic sclerosis: a systematic review.

  2014cited by this paper
• The Primary Care Physician in the Early Diagnosis of Systemic Sclerosis: The Cornerstone of Recognition and Hope

  2014cited by this paper
• Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

  2014cited by this paper
• Screening of human papillomavirus infection in women with systemic sclerosis.

  2014cited by this paper
• Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases

  2014cited by this paper
• 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

  2014cited by this paper
• Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis.

  2014cited by this paper
• Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey.

  2014cited by this paper
• Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

  2013cited by this paper
• Evidence-based management of hand and mouth disability in a woman living with diffuse systemic sclerosis (scleroderma).

  2013cited by this paper
• Sleep quality in patients with systemic sclerosis: relationship between the clinical variables, depressive symptoms, functional status, and the quality of life

  2013cited by this paper
• Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

  2013cited by this paper

• Serum pentraxin 3 in relation to clinical and nailfold capillaroscopy findings in patients with systemic sclerosis

  2025cites this paper
• Basic concepts in preserving holistic well-being in interstitial lung diseases: A MIHRA and G-FoRSS collaborative summary

  2024cites this paper
• The burden of illness of the organ manifestations of systemic sclerosis: a pragmatic, targeted review.

  2024cites this paper
• Biomarkers in Systemic Sclerosis: An Overview

  2023cites this paper
• Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

  2023cites this paper